共 50 条
- [21] Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin LymphomaBLOOD, 2008, 112 (11) : 1049 - 1049Kuruvilla, JohnTaylor, DianeWang, LisaBlattler, ChantaleKeating, ArmandCrump, Michael
- [22] A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacyJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Wang, M.Fayad, L.Hagemeister, F.Neelapu, S.Bell, N.Byrne, C.Knight, R.Zeldis, J.Kwak, L.Romaguera, J.
- [23] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphomaLEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241Grieve, ClareJoseph, AshleeDrullinsky, PamelaZelenetz, Andrew D.Hamlin, PaulKumar, Anita
- [24] Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) - a Phase II Clinical TrialBLOOD, 2020, 136Jain, PreeteshYao, YixinZhao, ShuangtaoLiu, YangHill, HollyChe, YuxuanLi, YijingJordan, Alexa A.McIntosh, JosephLee, Hun JuSteiner, Raphael EricSamaniego, FelipeWestin, JasonNastoupil, Loretta J.Nair, RanjitAhmed, SairahOk, Chi YoungKanagal-Shamanna, RashmiOriabure, OnyekaXu, GuofangChen, WendyMoghrabi, OmarMcClain, Chloe MarieBadillo, MariaThirumurthi, SelviSantos, DavidIliescu, CezarYin, C. CameronLi, ShaoyingTang, GuilinVega, FranciscoNeelapu, Sattva S.Flowers, ChristopherWang, LinghuaWang, Michael
- [25] Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular LymphomaCANCER, 2011, 117 (11) : 2442 - 2451Baiocchi, Robert A.Alinari, LapoLustberg, Mark E.Lin, Thomas S.Porcu, PierluigiLi, XiaobaiJohnston, Jeffrey S.Byrd, John C.Blum, Kristie A.
- [26] A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphomaBLOOD ADVANCES, 2022, 6 (18) : 5262 - 5266Qualls, DavidLam, Hiu YingWhiting, KarissaKumar, AnitaMatasar, MatthewOwens, ColetteNichols, ChelseaEspeleta, James A.Qiu, AnnieSubzwari, SarimaBiggar, ErinSeshan, VenkatramanSalles, GillesYounes, AnasBatlevi, Connie
- [27] Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell LymphomaBLOOD, 2008, 112 (11) : 1051 - 1051Wang, MichaelZhang, LiangFayad, LuisHagemeister, FredrickNeelapu, SattvaSamaniego, FelipePro, BarbaraYounes, AnasMiller, ScottKnight, Robert D.Zeldis, Jerome B.Yi, QingRomaguera, Jorge
- [28] Lenalidomide (Len) in combination with rituximab (R) demonstrated early evidence of efficacy in a phase I/II study in relapsed/refractory mantle cell lymphoma (MCL)BLOOD, 2007, 110 (11) : 755A - 755AWang, MichaelFayad, LuisHagemeister, FrederickNeelapu, SattvaSamuels, BarrySamanigo, FelipePro, BarbaraYi, QingBell, NedaByrne, CatrionaWeaver, PamHartig, KimKnight, RobertZeldis, JerryKwak, LarryRomaguera, Jorge
- [29] Lenalidomide in combination with rituximab is effective with manageable toxicity in a phase I/II study in relapsed/refractory mantle cell lymphomaANNALS OF ONCOLOGY, 2008, 19 : 174 - 174Wang, M.Fayad, L.Hagemeister, F.Neelapu, S.Samuels, B.Samanigo, F.Pro, B.Yi, Q.Bell, N.Byrne, C.Weaver, P.Hartig, K.Knight, R.Zeldis, J.Kwak, L.Romaguera, J.
- [30] Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II TrialBLOOD, 2019, 134Jain, PreeteshLee, Hun JuSteiner, Raphael EricHagemeister, F. B.Samaniego, FelipeWestin, Jason R.Nastoupil, Loretta J.Ahmed, SairahIyer, Swaminathan P.Romaguera, Jorge EnriqueZhao, ShuangtaoNomie, KrystleOk, Chi YoungKanagal-Shamanna, RashmiOriabure, OnyekaXu, GuofangZhang, LiangJiang, ChangyingJung, DayoungNavsaria, LucyChen, WendyMoghrabi, OmarNizam, TayyabaMcClain, Chloe MarieBadillo, MariaThirumurthi, SelviSantos, DavidTang, GuilinPatel, KeyurNeelapu, Sattva S.Wang, LinghuaFowler, Nathan H.Wang, Michael L.